Effects of Acute Intermittent Hypoxia on Neuroplasticity in MS
Launched by SHIRLEY RYAN ABILITYLAB · Apr 25, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how a specific breathing technique, called Acute Intermittent Hypoxia (AIH), might improve arm and hand function in people with Multiple Sclerosis (MS). AIH involves breathing in low levels of oxygen for short periods and has shown promise in increasing strength in the ankles of MS patients. In this study, researchers will measure how this breathing method affects muscle responses and the signals from the brain to the arm muscles, both before and after the intervention.
To participate in the trial, individuals must have a diagnosis of relapsing-remitting MS for at least five years and be free from relapses for the past six months. They should also meet certain strength criteria in their hands. The study is open to adults aged 27 to 74, and all genders are welcome. Participants will undergo assessments to evaluate their arm function and muscle responses, helping researchers understand if AIH can be beneficial for MS patients. It’s important to note that individuals with certain other medical conditions or who are pregnant cannot take part in this trial.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of relapsing-remitting MS according to the McDonald criteria, over 5 years ago
- • Relapse free for at least 6 months
- • Expanded Disability Status Scale (EDSS) ≤7
- • Index finger abduction strength \<5 according to Medical Research Council Scale, or 9-Hole Peg Test score \>20 seconds in at least one hand
- • Stable disease modifying therapies for at least 6 months
- • Individuals taking dalfampridine will be eligible if taking the same daily dose for at least 2 months prior to screening
- Exclusion Criteria:
- • Another diagnosis (e.g., peripheral neuropathies or orthopedic) affecting upper limb function
- • Mini-Mental State Examination (MMSE) score \<24
- • Modified Ashworth Scale score \>3 on elbow joint
- • Uncontrolled hypertension or hypotension (outside 140/90 and 85/55 mmHg)
- • History of epilepsy, chronic obstructive pulmonary disease, or sleep apnea
- • Unstable medical conditions, ongoing upper limb therapy, or musculoskeletal pain
- • Pregnancy as confirmed by urine test
About Shirley Ryan Abilitylab
Shirley Ryan AbilityLab is a leading research and rehabilitation institute dedicated to advancing the science of physical medicine and rehabilitation. Based in Chicago, Illinois, the organization integrates clinical care, research, and education to enhance the quality of life for individuals with disabilities and chronic conditions. Known for its innovative approach, Shirley Ryan AbilityLab conducts clinical trials that aim to develop and evaluate cutting-edge therapies and technologies, fostering a collaborative environment that bridges the gap between laboratory research and patient care. Through its commitment to excellence, the institute strives to empower patients and improve outcomes in rehabilitation medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chicago, Illinois, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported